CagriReta
Cagrilintide + Retatrutide Combination Vial
Amylin-analogue cagrilintide combined with triple-agonist retatrutide for researchers exploring additive satiety and energy-balance pathways. Available in 5 mg and 10 mg sizes.
Fat Loss / Metabolic
Category
From $116.99
Price
Research
Grade
Price
From $116.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
Parallel titration of both components according to their individual published schedules. Cagrilintide: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg weekly, 4 weeks per step. Retatrutide: 0.5mg → 1mg → 2mg → 4mg → 8mg weekly, 4 weeks per step. Total titration envelope ~20 weeks, but early signals on tolerability emerge within the first 8 weeks — which is the window this 5mg vial covers.
The 5mg Cagri-Reta format exists for the research question that comes first: is the four-receptor-class combination tolerable in the specific research model before committing to a maintenance-scale protocol? Titration for this blend takes 8-12 weeks because both components must ramp slowly to manage GI tolerability — cagrilintide from 0.25mg up through 2.4mg weekly, retatrutide from 0.5mg up through 8-12mg weekly. Across that titration envelope, combined peptide consumption is modest: roughly 3-4mg total across 8 weeks. The 5mg blend covers that ramp cleanly.
Specifications
| Product | CagriReta |
|---|---|
| Category | Fat Loss / Metabolic |
| Format | Lyophilized powder |
| Price | From $116.99 |
Pilot Scale Math
Why 5mg Covers Titration, 10mg Covers Maintenance
Titration across both components in parallel consumes ~3-4mg of total peptide across the first 8 weeks of a research arm. A 5mg blend covers that window with small headroom for low-maintenance use beyond it. For sustained research at full combined maintenance doses (2.4mg cagrilintide + 8-12mg retatrutide weekly), the 10mg format's larger peptide budget becomes necessary.
The Tolerability Question
What This Blend Specifically Helps Answer
Before committing to 12+ weeks of maintenance research, investigators need to know whether the combined GI effect profile is manageable in their research model. Cagrilintide delays gastric emptying; retatrutide adds incretin-class GI effects plus glucagon-receptor engagement. The 5mg pilot format lets researchers observe tolerability through titration before the maintenance-commitment decision.
Investigational Status Caveat
Same as 10mg: No Clinical Validation Yet
The cagrilintide-retatrutide combination is untested in pivotal trials. Pharmacodynamic interaction, long-term safety, and clinical endpoint effects are all unvalidated. This pilot blend is for preclinical or exploratory research specifically — it should not be used for clinical-replication protocols, which do not exist for this combination.
Reported Outcomes
2.5mg cagrilintide + 2.5mg retatrutide — pilot-scale of the four-receptor blend
Covers the full 8-12 week titration ramp for a single research subject
Addresses the tolerability question before committing to maintenance-scale inventory
Lower cost entry point for investigators evaluating whether to continue to 10mg
Same four-receptor-class engagement logic as the bulk blend
Phiogen co-lyophilised with component-level COA on both actives
Best Stacked With
Research Protocol
Parallel titration of both components according to their individual published schedules. Cagrilintide: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg weekly, 4 weeks per step. Retatrutide: 0.5mg → 1mg → 2mg → 4mg → 8mg weekly, 4 weeks per step. Total titration envelope ~20 weeks, but early signals on tolerability emerge within the first 8 weeks — which is the window this 5mg vial covers.
CagriReta — FAQs
Related Fat Loss / Metabolic Research
View All
Mazdutide 6mg
Mazdutide (IBI362) — Innovent Biologics' long-acting GLP-1/glucagon dual agonist, the oxyntomodulin analog licensed from Eli Lilly that received Chinese NMPA approval in 2025 for obesity and T2D.
Tesofensine 500mcg x30 Tablets
The pressed-tablet format — identical 500mcg tesofensine dose as the capsule variant, differentiated by faster GI disintegration kinetics and the practical option to split the tablet for lower-dose titration research.
